749 Infliximab for Prevention of Recurrence of Post-Surgical Crohn's Disease Following Ileocolonic Resection: A Randomized, Placebo-Controlled Study
Miguel Regueiro, Paul Rutgeerts(KU Leuven), Marc Chévrier(Janssen (United States)), William Sandborn, Silvio Danese(IRCCS Ospedale San Raffaele), Brian G. Feagan(Western University), Marion Blank(Janssen (United States)), Freddy Cornillie(MSD (Switzerland)), Paolo Gionchetti(IRCCS Azienda Ospedliero-Universitaria di Bologna Policlinico di Sant'Orsola), Bin Zou(Janssen (United States)), Dario Sorrentino, Mark R. Molenda, Walter Reinisch(Medical University of Vienna), Jay Popp, Scott E. Plevy(Protagonist Therapeutics (United States)), Stephen B. Hanauer(Northwestern University), Jewel Johanns(Johnson & Johnson (United States)), Milan Lukáš(Charles University)
Cited by 9
Related Papers
Infliximab for Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2005|3.9k
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
|New England Journal of Medicine|2013|2.9k
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
|New England Journal of Medicine|2013|2.7k
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
|Gastroenterology|2021|2.6k
Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease
|Nature Genetics|2008|2.6k